Janux Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Janux Therapeutics Depreciation & Amortization Growth & History (JANX)
Janux Therapeutics's depreciation and amortization was $2.0M for fiscal 2025.
View full Janux Therapeutics company overviewJanux Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.0M | −$31,000 | −1.50% |
| 2024 | 2024-12-31 | $2.1M | $105,000 | +5.37% |
| 2023 | 2023-12-31 | $2.0M | $1.1M | +132.46% |
| 2022 | 2022-12-31 | $841,000 | $728,000 | +644.25% |
| 2021 | 2021-12-31 | $113,000 | $100,000 | +769.23% |
| 2020 | 2020-12-31 | $13,000 | — | — |
Janux Therapeutics quarterly depreciation and amortization
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $463,000 | −$78,000 | −14.42% |
| Q1 2026 | 2026-03-31 | $469,000 | −$50,000 | −9.63% |
| Q4 2025 | 2025-12-31 | $468,000 | — | — |
| Q3 2025 | 2025-09-30 | $501,000 | −$9,000 | −1.76% |
| Q2 2025 | 2025-06-30 | $541,000 | $35,000 | +6.92% |
| Q1 2025 | 2025-03-31 | $519,000 | −$13,000 | −2.44% |
| Q3 2024 | 2024-09-30 | $510,000 | $10,000 | +2.00% |
| Q2 2024 | 2024-06-30 | $506,000 | $35,000 | +7.43% |
| Q1 2024 | 2024-03-31 | $532,000 | $79,000 | +17.44% |
| Q3 2023 | 2023-09-30 | $500,000 | $251,000 | +100.80% |
| Q2 2023 | 2023-06-30 | $471,000 | $363,000 | +336.11% |
| Q1 2023 | 2023-03-31 | $453,000 | $372,000 | +459.26% |
| Q3 2022 | 2022-09-30 | $249,000 | $222,000 | +822.22% |
| Q2 2022 | 2022-06-30 | $108,000 | $95,000 | +730.77% |
| Q1 2022 | 2022-03-31 | $81,000 | $72,000 | +800.00% |
| Q3 2021 | 2021-09-30 | $27,000 | $26,000 | +2600.00% |
| Q2 2021 | 2021-06-30 | $13,000 | — | — |
| Q1 2021 | 2021-03-31 | $9,000 | — | — |
| Q3 2020 | 2020-09-30 | $1,000 | — | — |
Janux Therapeutics depreciation and amortization trends
Over the last five fiscal years, Janux Therapeutics's depreciation and amortization increased from $13,000 to $2.0M, a change of $2.0M. The latest reported quarter, Q2 2026, shows $463,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Janux Therapeutics source filings ↗